0.72 -0.02 (-2.70%)

89.25% Fall from 52W High

31,041 XNAS Volume

XNAS 19 Mar, 2025 11:30 AM (EDT)



Insider Trading disclosures for ZyVersa Therapeutics Inc

The latest disclosure was made by Sapirstein James in ZyVersa Therapeutics Inc where a trade of 132 Stock Options done was reported to US exchanges on May 24, 2023.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Sapirstein James Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 May 2023 132 132 - - Stock Options
Finizio G. Robert Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 May 2023 132 132 - - Stock Options
Gregory G. Freitag Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 May 2023 132 132 - - Stock Options
Park Min-Chul Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 May 2023 132 132 - - Stock Options
Wolfe Peter Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 May 2023 715 715 - - Stock Options
A. Cashmere Karen Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 May 2023 572 572 - - Stock Options
Pablo A. Guzman Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2023 100,000 100,000 - - Stock Options (right to buy)
Peter Wolfe Chief Financial Officer Grant, award, or other acquisition of securities at price $ 2.88 per share. 16 Dec 2022 3,000 44,585 - 2.9 8,645 Common Stock
Karen A. Cashmere Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 9,927 9,927 - - Stock Options (right to buy)
Karen A. Cashmere Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 19,854 19,854 - - Stock Options (right to buy)
Karen A. Cashmere Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 29,781 29,781 - - Stock Options (right to buy)
Karen A. Cashmere Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 21,840 21,840 - - Stock Options (right to buy)
Karen A. Cashmere Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 21,840 21,840 - - Stock Options (right to buy)
Peter Wolfe Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 11,763 11,763 - - Warrant (right to buy)
Peter Wolfe Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 18,058 18,058 - - Warrant (right to buy)
Peter Wolfe Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 21,840 21,840 - - Stock Options (right to buy)
Peter Wolfe Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 21,840 21,840 - - Stock Options (right to buy)
Peter Wolfe Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 39,708 39,708 - - Stock Options (right to buy)
Peter Wolfe Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 9,927 9,927 - - Stock Options (right to buy)
Peter Wolfe Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 9,927 9,927 - - Stock Options (right to buy)
Peter Wolfe Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 41,585 41,585 - - Common Stock
Min-Chul Park Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 9,927 9,927 - - Stock Options (right to buy)
Min-Chul Park Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 29,781 29,781 - - Stock Options (right to buy)
Robert G. Finizio Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 29,781 29,781 - - Stock Options (right to buy)
Robert G. Finizio Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 9,927 9,927 - - Stock Options (right to buy)
Robert G. Finizio Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 19,854 19,854 - - Stock Options (right to buy)
Nicholas A. LaBella Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 59,563 59,563 - - Stock Options (right to buy)
Nicholas A. LaBella Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 18,094 18,094 - - Warrant (right to buy)
Nicholas A. LaBella Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 39,709 39,709 - - Stock Options (right to buy)
Nicholas A. LaBella Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 19,854 19,854 - - Stock Options (right to buy)
Nicholas A. LaBella Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 18,094 18,094 - - Common Stock
Nicholas A. LaBella Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 39,708 39,708 - - Stock Options (right to buy)
Nicholas A. LaBella Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 29,781 29,781 - - Stock Options (right to buy)
Nicholas A. LaBella Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2022 29,781 29,781 - - Stock Options (right to buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures